The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
Open accessAbstract
Certain chemical modifications confer increased stability and low immunogenicity to in vitro transcribed mRNAs, thereby facilitating expression of therapeutically important proteins. Here, we demonstrate that N1-methyl-pseudouridine (N1mΨ) outperforms several other nucleoside modifications and their combinations in terms of translation capacity. Through extensive analysis of various modified transcripts in cell-free translation systems, we deconvolute the different components of the effect on protein expression independent of mRNA stability mechanisms. We show that in addition to turning off the immune/eIF2α phosphorylation-dependent inhibition of translation, the incorporated N1mΨ nucleotides dramatically alter the dynamics of the translation process by increasing ribosome pausing and density on the mRNA. Our results indicate that the increased ribosome loading of modified mRNAs renders them more permissive for initiation by favoring either ribosome recycling on the same mRNA or de novo ribosome recruitment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Unmodified, but not modified, mRNAs induce eIF2α phosphorylation and RNA-dependent protein kinase (PKR) activation in cell extracts. (A–D) Western blot analyzes of eIF2α phosphorylation in RNase untreated RRL (A, top panel), Krebs (B and C) or HeLa (D) S10 extracts not supplemented (none) or supplemented with unmodified or 5 mC/Ψ, 5 mC/N1mΨ, 5 mC and N1mΨ-incorporated Luc or GFP mRNAs (4 μg/ml), as indicated. GADD34 (6 μg/ml), either alone or in combination with K3L (16 μg/ml), was present where indicated. Extracts were either not incubated (RRL, Krebs S10 and HeLa S10) or incubated at 30°C for 30 min (A, top panel) or 60 min (B–D). The blots for Phospho-eIF2α (eIF2α-P) and total eIF2α (loading control) are shown. Phosphorylation (band intensity) of eIF2α normalized to the phosphorylation in the mRNA minus samples (none) is indicated below each panel. Asterisks indicate unspecific bands. (A, bottom panel) Phosphorylation states of eIF2α in RRL as analyzed by a combination of isoelectric focusing and western blotting. Arrows indicate the positions of phosphorylated and unphosphorylated forms of eIF2α. (E) Effects of unmodified and N1mΨ-incorporated mRNAs on protein phosphorylation in HeLa S10 extract. The assays were conducted in the absence (none) or presence of unmodified or N1mΨ-incorporated Luc and GFP mRNAs and [γ-32P]ATP as indicated. Molecular mass markers are indicated on the left. Arrow indicates the position of a phosphorylated 68-kDa protein.](/paper-figures/2a0950b2eec44565a27bb30569e63ad8/n1-methyl-pseudouridine-in-mrna-enhances-translation-through-eif2-dependent-and-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nucleoside-modified mRNA can reduce the activation of TLRs, retinoic acid-inducible gene I (RIG-I), protein kinase R (PKR), and 2′-5′-oligoadenylate synthetase (OAS). Additionally, nucleoside modification increases translation activity and resistance against RNase L-mediated degradation.54,81,173–176”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012) · Cell · doi:10.1016/j.cell.2012.05.003 · Cited by 4,223
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Ingolia, N. T., Lareau, L. F., & Weissman, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.10.002 · Cited by 2,187
Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins
Castello, A., Fischer, B., Eichelbaum, K., Horos, R., Beckmann, B. M., Strein, C., Davey, N. E., Humphreys, D. T., Preiss, T., Steinmetz, L. M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.031 · Cited by 2,132
5′ UTR m6A Promotes Cap-Independent Translation
Meyer, K. D., Patil, D. P., Zhou, J. L., Zinoviev, A., Skabkin, M. A., Elemento, O., Pestova, T. V., Qian, S., & Jaffrey, S. R. (2015) · Cell · doi:10.1016/j.cell.2015.10.012 · Cited by 1,812
Feedback Inhibition of the Unfolded Protein Response by GADD34-Mediated Dephosphorylation of eIF2α
Novoa, I., Zeng, H., Harding, H. P., & Ron, D. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.1011 · Cited by 1,434
Cited by
Sorted by citations
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
mRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555
Self-citationmRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507
RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo
Wesselhoeft, R. A., Kowalski, P. S., Parker-Hale, F. C., Huang, Y., Bisaria, N., & Anderson, D. G. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.015 · Cited by 482
Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Nance, K. D., & Meier, J. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00197 · Cited by 466
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19486-2 · Cited by 457
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
RNA modifications in physiology and disease: towards clinical applications
Delaunay, S., Helm, M., & Frye, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00645-2 · Cited by 368
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. A. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 349
Suzuki, Y., & Ishihara, H. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100424 · Cited by 323
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Morais, P., Adachi, H., & Yu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789427 · Cited by 281
Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents
Blanchard, E. L., Vanover, D. A., Bawage, S. S., Tiwari, P. M., Rotolo, L., Beyersdorf, J. P., Peck, H. E., Bruno, N. C., Hincapie, R., Michel, F. J., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00822-w · Cited by 244
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 252
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229
N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting
Mulroney, T. E., Pöyry, T. A. A., Yam‐Puc, J. C., Rust, M., Harvey, R. F., Kalmár, L., Horner, E. C., Booth, L. H., Ferreira, A., Stoneley, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06800-3 · Cited by 241
Xue, L., Gong, N., Shepherd, S. J., Xiong, X., Liao, X., Han, X., Zhao, G., Song, C., Huang, X., Zhang, H., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02706 · Cited by 191
Nucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 225
Carlsson, L. G., Clarke, J. C., Yen, C. Y. T., Gregoire, F. M., Albery, T., Billger, M. A., Egnell, A., Gan, L., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 186
mRNA-Based Protein Replacement Therapy for the Heart
Magadum, A., Kaur, K., & Zangi, L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.018 · Cited by 176
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
Inosine induces context-dependent recoding and translational stalling
Licht, K., Hartl, M., Amman, F., Anrather, D., Janisiw, M. P., & Jantsch, M. F. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1163 · Cited by 159
Van der Jeught, K., De Koker, S., Bialkowski, L., Heirman, C., Tjok Joe, P., Perche, F., Maenhout, S., Bevers, S., Broos, K., Deswarte, K., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00966 · Cited by 139
Immunogenicity of In Vitro -Transcribed RNA
Mu, X. N., & Hur, S. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00521 · Cited by 143
Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes
Dhaliwal, H. K., Fan, Y., Kim, J., & Amiji, M. M. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00170 · Cited by 137
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
Rijkers, G. T., Weterings, N., Obregón‐Henao, A., Dutt, T., Dutt, T. S., van Overveld, F. J., & Henao-Tamayo, M. I. (2021) · Vaccines · doi:10.3390/vaccines9080848 · Cited by 139
Amplifying gene expression with RNA-targeted therapeutics
Khorkova, O., Stahl, J., Joji, A., Volmar, C., & Wahlestedt, C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00704-7 · Cited by 136
N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells
Parr, C., Wada, S., Kotake, K., Kameda, S., Matsuura, S., Sakashita, S., Park, S., Sugiyama, H., Kuang, Y., & Saito, H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa070 · Cited by 121
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 122
Sayers, E. J., Peel, S. E., Schantz, A., England, R., Beano, M., Bates, S. M., Desai, A. S., Puri, S., Ashford, M. B., & Jones, A. T. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.018 · Cited by 119
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 119
Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases
Sahu, I., Haque, A. K. M. A., Weidensee, B., Weinmann, P., & Kormann, M. S. D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.019 · Cited by 104
Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications
Patel, S., Athirasala, A., Menezes, P. D. P., Ashwanikumar, N., Zou, T., Sahay, G., & Bertassoni, L. E. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0444 · Cited by 101
Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery
Melamed, J. R., Hajj, K. A., Chaudhary, N., Strelkova, D., Arral, M. L., Pardi, N., Alameh, M., Miller, J. B., Farbiak, L., Siegwart, D. J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.022 · Cited by 101
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100
The Pivotal Role of Chemical Modifications in mRNA Therapeutics
Liu, A., & Wang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.901510 · Cited by 102
Synthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
A New Era for Rare Genetic Diseases: Messenger RNA Therapy
Martini, P. G. V., & Guey, L. T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.090 · Cited by 88
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 94
Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
Deal, C. E., Carfı́, A., & Plante, O. J. (2021) · Vaccines · doi:10.3390/vaccines9020108 · Cited by 90
Ripoll, M., Bernard, M., Vaure, C., Bazin, E., Commandeur, S., Perkov, V., Lemdani, K., Nicolaï, M., Bonifassi, P., Kichler, A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121570 · Cited by 89
mRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85
Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
Duan, L.-J., Wang, Q., Zhang, C., Yang, D.-X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923647 · Cited by 83
Moradian, H., Roch, T., Anthofer, L., Lendlein, A., & Gossen, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.004 · Cited by 77
N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation
Monroe, J. G., Eyler, D. E., Mitchell, L., Deb, I., Bojanowski, A., Srinivas, P., Dunham, C. M., Roy, B., Frank, A. T., & Koutmou, K. S. (2024) · Nature Communications · doi:10.1038/s41467-024-51301-0 · Cited by 83
Post-transcriptional control of gene expression following stress: the role of RNA-binding proteins
Harvey, R. F., Dezi, V., Pizzinga, M., & Willis, A. E. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160364 · Cited by 77
Liu, J., Zhang, Y., Liu, C., Jiang, Y., Wang, Z., Guo, Z., & Li, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.018 · Cited by 77
Translation—A tug of war during viral infection
Rozman, B., Fisher, T., & Stern‐Ginossar, N. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.10.012 · Cited by 75
Delivery of therapeutic oligonucleotides in nanoscale
Wu, L., Zhou, W., Lin, L., Chen, A., Feng, J. C., Qu, X., Zhang, H., & Yue, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.038 · Cited by 72
Chu, J.-M., Ye, T.-T., Ma, C.-J., Lan, M., Liu, T., Yuan, B., & Feng, Y. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00906 · Cited by 70
Strzelecka, D., Śmietański, M., Sikorski, P. J., Warmiński, M., Kowalska, J., & Jemielity, J. (2020) · RNA · doi:10.1261/rna.077099.120 · Cited by 68
Simultaneous nanopore profiling of mRNA m6A and pseudouridine reveals translation coordination
Huang, S., Wylder, A. C., & Pan, T. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02135-0 · Cited by 65
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 72
N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products
Kim, K. Q., Burgute, B. D., Tzeng, S., Jing, C., Jungers, C. F., Zhang, J., Yan, L. L., Vierstra, R. D., Djuranović, S., Evans, B. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111300 · Cited by 69
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Bernard, M., Bazin, E., Petiot, N., Lemdani, K., Commandeur, S., Verdelet, C., Margot, S., Perkov, V., Ripoll, M., Garinot, M., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.004 · Cited by 63
Lyu, X., Yang, Q., Zhao, F., & Liu, Y. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab729 · Cited by 64
The vasculature: a therapeutic target in heart failure?
Luxán, G., & Dimmeler, S. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab047 · Cited by 61
Wu, H., Peng, Z., Xu, Y., Sheng, Z., Liu, Y., Liao, Y., Wang, Y., Wen, Y., Yi, J., Xie, C., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02695-x · Cited by 59
Bérouti, M., Wagner, M., Greulich, W., Piseddu, I., Gärtig, J., Hansbauer, L., Müller-Hermes, C., Heiß, M., Pichler, A., Tölke, A. J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.032 · Cited by 66
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 63
Human RNase 4 improves mRNA sequence characterization by LC–MS/MS
Wolf, E. J., Grünberg, S., Dai, N., Chen, T.-H., Roy, B., Yigit, E., & Junior, I. R. C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac632 · Cited by 56
Lin, S., & Kuang, M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00884-y · Cited by 58
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics
Muslimov, A. R., Tereshchenko, V., Shevyrev, D., Rogova, A. S., Lepik, K. V., Reshetnikov, V. V., & Ivanov, R. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914820 · Cited by 51
Exogenous RNA surveillance by proton-sensing TRIM25
Kim, M., Pyo, Y., Hyun, S., Jeong, M., Choi, Y., & Kim, V. N. (2025) · Science · doi:10.1126/science.ads4539 · Cited by 49
mRNA Vaccines: Why Is the Biology of Retroposition Ignored?
Domazet‐Lošo, T. (2022) · Genes · doi:10.3390/genes13050719 · Cited by 47
Tang, X., Huo, M., Chen, Y., Huang, H., Qin, S., Luo, J., Qin, Z., Jiang, X., Liu, Y., Duan, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.003 · Cited by 47
Regulators of mitonuclear balance link mitochondrial metabolism to mtDNA expression
Kramer, N. J., Prakash, G., Isaac, R. S., Choquet, K., Soto, I. C., Petrova, B., Merens, H. E., Kanarek, N., & Churchman, L. S. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01244-3 · Cited by 46
Dobrovolskaia, M. A., & Bathe, M. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1657 · Cited by 45
Steinle, H., Weber, M., Behring, A., Mau-Holzmann, U. A., OHLE, C. V., Popov, A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.07.016 · Cited by 43
Thatte, A. S., Hamilton, A. G., Nachod, B. E., Mukalel, A. J., Billingsley, M. M., Palanki, R., Swingle, K. L., & Mitchell, M. J. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c02573 · Cited by 47
Chemical modifications to mRNA nucleobases impact translation elongation and termination
Franco, M. K., & Koutmou, K. S. (2022) · Biophysical Chemistry · doi:10.1016/j.bpc.2022.106780 · Cited by 47
Stronger together for in-cell translation: natural and unnatural base modified mRNA
Bornewasser, L., Domnick, C., & Kath‐Schorr, S. (2022) · Chemical Science · doi:10.1039/d2sc00670g · Cited by 43
N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs
Chen, T.-H., Potapov, V., Dai, N., Ong, J. L., & Roy, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-17249-1 · Cited by 44
Optimizing Modified mRNA In Vitro Synthesis Protocol for Heart Gene Therapy
Hadas, Y., Sultana, N., Youssef, E., Sharkar, M. T. K., Kaur, K., Chepurko, E., & Zangi, L. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.07.006 · Cited by 41
Pseudouridines in RNAs: switching atoms means shifting paradigms
Lin, T., Mehta, R., & Glatt, S. (2021) · FEBS Letters · doi:10.1002/1873-3468.14188 · Cited by 42
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
Miller, J. B., & Siegwart, D. J. (2018) · Nano Research · doi:10.1007/s12274-018-2099-4 · Cited by 41
A Census and Categorization Method of Epitranscriptomic Marks
Mathlin, J., Pera, L. L., & Colombo, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134684 · Cited by 41
The Epitranscriptome in Translation RegulationPreprint
Peer, E., Moshitch-Moshkovitz, S., Rechavi, G., & Dominissini, D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032623 · Cited by 41
Strong Immune Responses Induced by Direct Local Injections of Modified mRNA-Lipid Nanocomplexes
Arya, S., Lin, Q., Zhou, N., Gao, X., & Huang, J.-D. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.12.044 · Cited by 39
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy
Pan, S., Fan, R., Han, B. R., Tong, A., & Guo, G. F. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.003 · Cited by 39
Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy
Jiang, Y., Zhang, Y., Liu, C., Liu, J., Xue, W., Wang, Z., & Li, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.016 · Cited by 38
Nakanishi, H., Yoshii, T., Kawasaki, S., Hayashi, K., Tsutsui, K., Oki, C., Tsukiji, S., & Saito, H. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.002 · Cited by 38
McErlean, E. M., & McCarthy, H. O. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02746-4 · Cited by 42
RNA-based therapy for osteogenesis
Wang, P., Perche, F., Logeart‐Avramoglou, D., & Pichon, C. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118594 · Cited by 38
Regulatory Considerations on the Development of mRNA Vaccines
Naik, R., & Peden, K. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_220 · Cited by 37
Svitkin, Y. V., Gingras, A., & Sonenberg, N. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1241 · Cited by 38
Self-citationDemystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 36
Effects of mRNA Modifications on Translation: An Overview
Roy, B. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1374-0_20 · Cited by 36
Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome
Grimm, N.-B., & Lee, J. T. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.01.007 · Cited by 34
Synthesis of point-modified mRNA
Hertler, J., Slama, K., Schober, B., Özrendeci, Z., Marchand, V., Motorin, Y., & Helm, M. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac719 · Cited by 35
RNase H-based analysis of synthetic mRNA 5′ cap incorporation
Chan, S., Whipple, J. M., Dai, N., Kelley, T. M., Withers, K., Tzertzinis, G., Junior, I. R. C., & Robb, G. B. (2022) · RNA · doi:10.1261/rna.079173.122 · Cited by 32
Nakanishi, H., & Saito, H. (2020) · Nature Communications · doi:10.1038/s41467-020-15061-x · Cited by 32
Metadata
- Authors
- Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N.
- Affiliations
- Institut du cancer Rosalind & Morris Goodman (CA)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Svitkin, Yuri V.
- Sonenberg, Nahum
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-23
- Volume
- 45
- Issue
- 10
- Pages
- 6023-6036
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5449617
- OpenAlex
- W2589945527
- Cited by
- 278
- References
- 63
- Citations by year
- 2026: 38 · 2025: 49 · 2024: 31 · 2023: 32 · 2022: 48 · 2021: 29 · 2020: 22 · 2019: 13 · 2018: 13 · 2017: 2
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nucleoside-modified mRNA, translation efficiency, eIF2α phosphorylation, ribosome density, ribosome pausing, ribosome recycling, in vitro translation, in vitro transcribed mRNA
- MeSH terms
- Animals, Cell Line, Cell-Free System, Enzyme Activation, Fibroblasts, HeLa Cells, Humans, Phosphorylation, Polyribosomes, Protein Processing, Post-Translational, Pseudouridine, RNA, RNA, Messenger, Transfection, Protein Biosynthesis, Eukaryotic Initiation Factor-2, eIF-2 Kinase, RNA Stability, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review